Nektar Therapeutics (NKTR)

56.23 -0.39 (-0.69%) USD  |  NASDAQ  |  Jun 09, 16:00
56.80 +0.57 (+1.01%) After-Hours: 04:08
More

Nektar Therapeutics SG&A Expense (Quarterly) : 13.44M for March 31, 2026

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for NKTR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Eli Lilly & Co. 2.934B
Aquestive Therapeutics, Inc. 10.98M
Esperion Therapeutics, Inc. 43.12M
Alumis, Inc. 18.61M
Tvardi Therapeutics, Inc. 2.14M